TY - JOUR
T1 - Genetic variation in genes regulating skeletal muscle regeneration and tissue remodelling associated with weight loss in chronic obstructive pulmonary disease
AU - COPDGene, ECLIPSE and SPIROMICS investigators
AU - Lakshman Kumar, Preeti
AU - Wilson, Ava C.
AU - Rocco, Alison
AU - Cho, Michael H.
AU - Wan, Emily
AU - Hobbs, Brian D.
AU - Washko, George R.
AU - Ortega, Victor E.
AU - Christenson, Stephanie A.
AU - Li, Xingnan
AU - Wells, J. Michael
AU - Bhatt, Surya P.
AU - DeMeo, Dawn L.
AU - Lutz, Sharon M.
AU - Rossiter, Harry
AU - Casaburi, Richard
AU - Rennard, Stephen I.
AU - Lomas, David A.
AU - Labaki, Wassim W.
AU - Tal-Singer, Ruth
AU - Bowler, Russel P.
AU - Hersh, Craig P.
AU - Tiwari, Hemant K.
AU - Dransfield, Mark
AU - Thalacker-Mercer, Anna
AU - Meyers, Deborah A.
AU - Silverman, Edwin K.
AU - McDonald, Merry Lynn N.
N1 - Funding Information:
M.N.M. is funded by the National Institutes of Health (NIH) (R00HL121087, R56HL153460 and R01HL153460) and the Parker B. Francis Fellowship programme. D.A.L. is funded by the National Institute for Health Research (NIHR)/University College Hospitals (UCLH) Biomedical Research Centre (BRC); he is an NIHR senior investigator. M.H.C. is funded by NIH (R01HL135142, R01 HL137927, and R01 HL14714). B.D.H. is funded by NIH (K08 HL136928). The COPDGene study was supported by Award Number U01 HL089897 and Award Number U01 HL089856 from the National Heart, Lung, and Blood Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Heart, Lung, and Blood Institute or the National Institutes of Health. COPDGene is also supported by the COPD Foundation through contributions made to an Industry Advisory Board comprised of AstraZeneca, Boehringer‐Ingelheim, Genentech, GlaxoSmithKline, Novartis, Pfizer, Siemens, and Sunovion. SPIROMICS was supported by contracts from the National Institutes of Health/National Heart, Lung, and Blood Institute (HHSN268200900013C, HHSN268200900014C, HHSN268200900015C, HHSN268200900016C, HHSN268200900017C, HHSN268200900018C, HHSN268200900019C, HHSN268200900020C), grants from the NIH/NHLBI (U01 HL137880 and U24 HL141762), and supplemented by contributions made through the Foundation for the NIH and the COPD Foundation from AstraZeneca/MedImmune; Bayer; Bellerophon Therapeutics; Boehringer‐Ingelheim Pharmaceuticals, Inc.; Chiesi Farmaceutici S.p.A.; Forest Research Institute, Inc.; GlaxoSmithKline; Grifols Therapeutics, Inc.; Ikaria, Inc.; Novartis Pharmaceuticals Corporation; Nycomed GmbH; ProterixBio; Regeneron Pharmaceuticals, Inc.; Sanofi; Sunovion; Takeda Pharmaceutical Company; and Theravance Biopharma and Mylan.
Funding Information:
R.T‐S. is a former employee and current shareholder of GSK the sponsor of the ECLIPSE study. She declares personal fees from Immunomet, Vocalis Health, Ena Respiratory and Teva. E.K.S. has received institutional grant support from GSK and Bayer. M.W. has received institutional grant support from Mereo BioPharma, Grifols, Vertex Pharmaceuticals, Bayer AG, ARCUS‐Med, Verona, and has been in consultancy roles for AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, and Takeda. G.R.W. has received institutional grant support from Janssen Pharmaceuticals and Boehringer Ingelheim and has been in consultancy roles for Boehringer Ingelheim, CSL Behring, Janssen Pharmaceuticals, Novartis and Vertex. G.R.W. is also a founder and equity holder of Quantitative Imaging Solutions, a data and image analytics company. W.W.L. reports grants from NIH/NHLBI, non‐financial support from Pulmonx and personal fees from Konica Minolta. M.H.C. has received grant funding from Bayer and GSK and speaking or consulting fees from Genentech, AstraZeneca, and Illumina. H.B.R. received institutional grant support from GlaxoSmithKline, AstraZeneca, and Boehringer Ingelheim and consultancy fees from Boehringer Ingelheim, Astellas Pharma and Omniox Inc. M.T.D. reports grants from NIH, Department of Defense, and the American Lung Association; contracted clinical trial support from AstraZeneca, Boehringer Ingelheim, Boston Scientific, Gala, GlaxoSmithKline, Nuvaira, PneumRx/BTG, and Pulmonx; travel from Pulmonx; and consulting fees from AstraZeneca, GlaxoSmithKline, Mereo, Quark, and Teva.
Publisher Copyright:
© 2021 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders.
PY - 2021/12
Y1 - 2021/12
N2 - Background: Chronic obstructive pulmonary disease (COPD) is the third leading cause of death globally. COPD patients with cachexia or weight loss have increased risk of death independent of body mass index (BMI) and lung function. We tested the hypothesis genetic variation is associated with weight loss in COPD using a genome-wide association study approach. Methods: Participants with COPD (N = 4308) from three studies (COPDGene, ECLIPSE, and SPIROMICS) were analysed. Discovery analyses were performed in COPDGene with replication in SPIROMICS and ECLIPSE. In COPDGene, weight loss was defined as self-reported unintentional weight loss > 5% in the past year or low BMI (BMI < 20 kg/m2). In ECLIPSE and SPIROMICS, weight loss was calculated using available longitudinal visits. Stratified analyses were performed among African American (AA) and Non-Hispanic White (NHW) participants with COPD. Single variant and gene-based analyses were performed adjusting for confounders. Fine mapping was performed using a Bayesian approach integrating genetic association results with linkage disequilibrium and functional annotation. Significant gene networks were identified by integrating genetic regions associated with weight loss with skeletal muscle protein–protein interaction (PPI) data. Results: At the single variant level, only the rs35368512 variant, intergenic to GRXCR1 and LINC02383, was associated with weight loss (odds ratio = 3.6, 95% confidence interval = 2.3–5.6, P = 3.2 × 10−8) among AA COPD participants in COPDGene. At the gene level in COPDGene, EFNA2 and BAIAP2 were significantly associated with weight loss in AA and NHW COPD participants, respectively. The EFNA2 association replicated among AA from SPIROMICS (P = 0.0014), whereas the BAIAP2 association replicated in NHW from ECLIPSE (P = 0.025). The EFNA2 gene encodes the membrane-bound protein ephrin-A2 involved in the regulation of developmental processes and adult tissue homeostasis such as skeletal muscle. The BAIAP2 gene encodes the insulin-responsive protein of mass 53 kD (IRSp53), a negative regulator of myogenic differentiation. Integration of the gene-based findings participants with PPI data revealed networks of genes involved in pathways such as Rho and synapse signalling. Conclusions: The EFNA2 and BAIAP2 genes were significantly associated with weight loss in COPD participants. Collectively, the integrative network analyses indicated genetic variation associated with weight loss in COPD may influence skeletal muscle regeneration and tissue remodelling.
AB - Background: Chronic obstructive pulmonary disease (COPD) is the third leading cause of death globally. COPD patients with cachexia or weight loss have increased risk of death independent of body mass index (BMI) and lung function. We tested the hypothesis genetic variation is associated with weight loss in COPD using a genome-wide association study approach. Methods: Participants with COPD (N = 4308) from three studies (COPDGene, ECLIPSE, and SPIROMICS) were analysed. Discovery analyses were performed in COPDGene with replication in SPIROMICS and ECLIPSE. In COPDGene, weight loss was defined as self-reported unintentional weight loss > 5% in the past year or low BMI (BMI < 20 kg/m2). In ECLIPSE and SPIROMICS, weight loss was calculated using available longitudinal visits. Stratified analyses were performed among African American (AA) and Non-Hispanic White (NHW) participants with COPD. Single variant and gene-based analyses were performed adjusting for confounders. Fine mapping was performed using a Bayesian approach integrating genetic association results with linkage disequilibrium and functional annotation. Significant gene networks were identified by integrating genetic regions associated with weight loss with skeletal muscle protein–protein interaction (PPI) data. Results: At the single variant level, only the rs35368512 variant, intergenic to GRXCR1 and LINC02383, was associated with weight loss (odds ratio = 3.6, 95% confidence interval = 2.3–5.6, P = 3.2 × 10−8) among AA COPD participants in COPDGene. At the gene level in COPDGene, EFNA2 and BAIAP2 were significantly associated with weight loss in AA and NHW COPD participants, respectively. The EFNA2 association replicated among AA from SPIROMICS (P = 0.0014), whereas the BAIAP2 association replicated in NHW from ECLIPSE (P = 0.025). The EFNA2 gene encodes the membrane-bound protein ephrin-A2 involved in the regulation of developmental processes and adult tissue homeostasis such as skeletal muscle. The BAIAP2 gene encodes the insulin-responsive protein of mass 53 kD (IRSp53), a negative regulator of myogenic differentiation. Integration of the gene-based findings participants with PPI data revealed networks of genes involved in pathways such as Rho and synapse signalling. Conclusions: The EFNA2 and BAIAP2 genes were significantly associated with weight loss in COPD participants. Collectively, the integrative network analyses indicated genetic variation associated with weight loss in COPD may influence skeletal muscle regeneration and tissue remodelling.
UR - http://www.scopus.com/inward/record.url?scp=85115104662&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85115104662&partnerID=8YFLogxK
U2 - 10.1002/jcsm.12782
DO - 10.1002/jcsm.12782
M3 - Article
C2 - 34523824
AN - SCOPUS:85115104662
VL - 12
SP - 1803
EP - 1817
JO - Journal of Cachexia, Sarcopenia and Muscle
JF - Journal of Cachexia, Sarcopenia and Muscle
SN - 2190-5991
IS - 6
ER -